Humana Inc. (NYSE:HUM) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA reduced its holdings in Humana Inc. (NYSE:HUM) by 0.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,326 shares of the insurance provider’s stock after selling 50 shares during the quarter. Primecap Management Co. CA’s holdings in Humana were worth $5,114,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of HUM. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. Riverview Trust Co acquired a new position in Humana during the first quarter worth about $34,000. Garde Capital Inc. purchased a new position in Humana in the first quarter valued at about $36,000. Transce3nd LLC acquired a new stake in shares of Humana during the 4th quarter valued at approximately $38,000. Finally, Whipplewood Advisors LLC boosted its stake in shares of Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider’s stock worth $45,000 after acquiring an additional 147 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HUM. Wells Fargo & Company set a $348.00 price objective on Humana in a report on Friday, July 18th. Morgan Stanley cut their price target on Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research note on Thursday, July 31st. Wall Street Zen lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Oppenheimer raised their target price on shares of Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a report on Thursday, May 1st. Finally, Raymond James Financial raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target on the stock in a report on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $281.62.

Humana Trading Down 0.3%

Shares of HUM stock opened at $255.96 on Friday. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72. The firm’s 50-day simple moving average is $237.21 and its 200-day simple moving average is $254.50. The firm has a market cap of $30.78 billion, a P/E ratio of 19.64, a PEG ratio of 1.51 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%. The company had revenue of $32.39 billion for the quarter, compared to analysts’ expectations of $31.85 billion. During the same period in the prior year, the business earned $6.96 EPS. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. As a group, equities analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.